Product Description
Aderamastat is a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases. MMP-12 plays a role in asthma pathophysiology and is associated with disease severity. Aderamastat showed sustained anti-inflammatory effects and attenuated allergen-induced histopathology in a mouse model of house dust-mite (HDM). Importantly, a Phase 2 allergen challenge asthma proof-of-concept study has been successfully completed. (Sourced from: https://www.benzinga.com/pressreleases/23/07/n33360879/foresee-pharmaceuticals-selected-for-late-breaking-oral-presentation-on-its-aderamastat-phase-2-st)
Mechanisms of Action: MMP12 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Foresee
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Netherlands
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: Asthma|Chronic Obstructive Pulmonary Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| FP02C-18-001 | P2 |
Completed |
Chronic Obstructive Pulmonary Disease|Asthma |
2022-12-30 |
|
| 2017-005164-17 | P2 |
Active, not recruiting |
Chronic Obstructive Pulmonary Disease|Asthma |
None |